Argon enters licensing agreement with Rex Medical for UltraStream catheter

Argon Medical Devices, Inc. announced today that it has entered into a definitive licensing agreement with Rex Medical, LP ("Rex Medical") for exclusive rights to market and distribute the UltraStream chronic dialysis catheter ™ on a global basis. UltraStreamis designed to provide long-term vascular access to patients receiving dialysis treatments.

Argon will be exhibiting at the 37th Veithsymposium™ to be held in New York City from November 17-21, 2010.

"The addition of UltraStream™ reinforces our commitment to providing physicians with innovative products focused on improving patient care," said George A. Leondis, President of Argon Medical Devices, Inc. "We are excited about this opportunity to further enhance our portfolio of products for use in the area of dialysis access, which also includes the Cleaner™ Rotational Thrombectomy System."

There are over 500,000 patients currently undergoing treatment in the U.S. for End-Stage Renal Disease (ESRD). It is estimated that the dialysis patient population will continue to grow at a rate exceeding 6% annually.

Source:

Argon Medical Devices, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New drug-releasing system eliminates tumors in 82% of high-risk bladder cancer patients